“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Rodrigo is a synthetic organic chemist with a background in various areas of chemistry. Rodrigo took his PhD from The Scripps Research Institute under the guidance of MacArthur Fellow Prof. Phil S. Baran, specializing in total synthesis with a focus on pyrrole imidazole alkaloids, a complex and notoriously challenging class of natural products. His work also included numerous methodological advancements, leading to the commercialization of various reagents by Sigma-Aldrich, particularly in C-C and C-X bond formation.
Rodrigo then transitioned to Novartis, where he completed ResMed medicinal chemistry courses at Drew University and contributed to Novartis drug discovery pipelines. His work involved hit-to-lead and lead optimization phases, impacting the success of several internal drug candidate selection processes. In total, Rodrigo has 22 published research works, of which 7 of them are industry patents. He has worked in multiple disease areas, including anti-infective, respiratory, and oncology programs, as well as in both classic small molecule modality and antibody drug conjugation modality. One of his notable medicinal chemistry achievements includes key contributions to a project resulting in the Best In Class compound of 2015 for Cystic Fibrosis.
His journey continued with Singular Genomics, where Rodrigo played a key role in the discovery and development of innovative reversible terminators. Beyond the lab, he helped establish a chemistry process development department, facilitating a successful commercial product launch and IPO exit.
Driven by his passion for early-stage discovery innovation, Rodrigo embarked on a journey with the DEL platform team at 1859, Inc. Here, he served as the Chemistry Lead for a cross-functional drug discovery team, directing his focus toward the automation of synthesis processes and integration of medicinal chemistry principles into library design. Furthermore, Rodrigo actively participated in partnership initiatives aimed at enabling hit identification through scaffold hop designs.
Today, Rodrigo brings his experience and dedication to GP. His mission is to contribute significantly to the field of induced-proximity medicines and improve human health by expanding accessibility to new druggable space.
